This podcast episode explores the rise of Osempic, a weight loss drug belonging to the GLP1 class of medications, and its impact on the medical and cultural contexts surrounding obesity. Osempic mimics a hormone to regulate appetite and make individuals feel fuller, which has shown effectiveness in helping people lose weight. However, the introduction of weight loss drugs like Osempic complicates the conversation around body size and beauty standards. The pharmaceutical company Novo Nordisk has played a significant role in developing and studying these drugs. The episode delves into the experiences of individuals who have used weight loss medications, highlighting both positive and negative effects. The use of such medications raises questions about personal choice, stigma, and societal expectations. Additionally, the episode discusses the effectiveness and side effects of these medications and the need for a nuanced understanding of individual choices and experiences. The presence of weight loss medications is likely to have a lasting impact on our culture and conversations around weight.
